BridgeMD
Tests treatment safety and results for Acute Kidney Injury
Official title The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
ClinicalTrials.gov ID: NCT06528405
What this study is testing
What is dapagliflozin?
dapagliflozin is an investigational medicine, being studied as a potential treatment for acute kidney injury.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age ≥ 18 years and \< 80 years
- Diagnosed with acute kidney disease
- Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73m²
- Albuminuria \> 100 mg/g or proteinuria \> 300 mg/g (adjusted by urine creatinine)
- Diagnosed with diabetes or chronic kidney disease
You likely can't join if
- Received sodium-glucose cotransporter 2 (SGLT2) inhibitors within 28 days prior to enrollment
- Patients with type 1 diabetes
- Receiving aggressive immunosuppressive therapy for glomerulonephritis
- Obstructive nephropathy
- Polycystic kidney disease
- Malignancy within 3 months or expected to undergo aggressive treatment such as chemotherapy, radiation therapy, immunotherapy, or targeted therapy in...
See the full eligibility criteria
- Age ≥ 18 years and \< 80 years
- Diagnosed with acute kidney disease
- Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73m²
- Albuminuria \> 100 mg/g or proteinuria \> 300 mg/g (adjusted by urine creatinine)
- Diagnosed with diabetes or chronic kidney disease
- Received sodium-glucose cotransporter 2 (SGLT2) inhibitors within 28 days prior to enrollment
- Patients with type 1 diabetes
- Receiving aggressive immunosuppressive therapy for glomerulonephritis
- Obstructive nephropathy
- Polycystic kidney disease
- Malignancy within 3 months or expected to undergo aggressive treatment such as chemotherapy, radiation therapy, immunotherapy, or targeted therapy in the future
- Pregnant or breastfeeding women
- Clinically assessed as not having recovered from acute kidney injury
- Clinically assessed as at high risk for complications related to SGLT2 inhibitors
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.